Epigral Stock Falls to 52-Week Low of Rs.1428 Amidst Sector Underperformance

Intraday Price Movement and Market Context

On 24 Nov 2025, Epigral's share price touched an intraday low of Rs.1428, reflecting a decline of 2.08% for the day. This performance lagged behind the Specialty Chemicals sector, underperforming by 0.85%. The stock's current price remains below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling sustained downward momentum over multiple time frames.

In contrast, the broader market benchmark, the Sensex, opened 88.12 points higher and was trading at 85,343.57, a 0.13% gain. The Sensex is approaching its 52-week high of 85,801.70, standing just 0.54% below that peak. The index has recorded a 2.56% rise over the past three weeks, supported by mega-cap stocks and a bullish alignment of its 50-day and 200-day moving averages.

Long-Term Price Performance and Valuation Metrics

Over the past year, Epigral's stock price has declined by 26.32%, contrasting with the Sensex's 7.85% gain during the same period. The stock's 52-week high was Rs.2195.85, indicating a substantial retracement from that level. This downward trend is consistent with the company's financial performance and valuation metrics.

Epigral's market capitalisation is graded at 3, reflecting its mid-tier size within the Specialty Chemicals sector. The stock is currently trading at a discount relative to its peers' historical valuations, with an enterprise value to capital employed ratio of 2.6. This valuation is supported by a return on capital employed (ROCE) of 19.3%, which suggests a fair assessment of the company's capital efficiency.

Financial Performance Indicators

Epigral's operating profit has shown a compound annual decline of 5.49% over the last five years, indicating subdued growth in core profitability. The latest quarterly results for September 2025 reveal a mixed picture: operating profit to net sales ratio stands at a low 22.53%, while profit after tax (PAT) for the quarter was Rs.51.22 crores, representing a 52.6% reduction compared to the average of the previous four quarters.

Interest expenses over the last six months have risen sharply to Rs.45.21 crores, a growth of 286.41%, which may have exerted pressure on net profitability. Despite these challenges, the company maintains a low debt to EBITDA ratio of 1.34 times, indicating a manageable debt servicing capacity.

Shareholding and Management Efficiency

The majority shareholding in Epigral is held by promoters, providing a stable ownership structure. The company's management efficiency is reflected in a high ROCE of 23.19%, underscoring effective utilisation of capital in generating returns.

Comparative Returns and Profitability Trends

While Epigral's stock price has declined by over a quarter in the last year, the company's profits have shown a 37.1% rise during the same period. This divergence between earnings growth and share price performance is notable. The price-to-earnings-to-growth (PEG) ratio stands at 0.5, suggesting that the stock's valuation is relatively low compared to its earnings growth rate.

However, the stock has underperformed the BSE500 index over the last three years, one year, and three months, indicating a consistent lag relative to a broad market benchmark.

Sector and Market Positioning

Epigral operates within the Specialty Chemicals industry, a sector that has seen mixed performance in recent months. Despite the broader market's upward trajectory, Epigral's share price has not aligned with sectoral or market gains, reflecting company-specific factors influencing investor sentiment.

The stock's current trading below all key moving averages suggests that short- and medium-term momentum remains subdued. This technical positioning may influence trading behaviour and price discovery in the near term.

Summary of Key Metrics

To summarise, Epigral's stock has reached a new 52-week low of Rs.1428, with a one-year price return of -26.32%. The company’s operating profit has declined at an annual rate of 5.49% over five years, while recent quarterly PAT has fallen by over half compared to prior averages. Interest costs have expanded significantly, though debt servicing remains manageable. The stock trades at a discount to peers with a fair ROCE and a low PEG ratio, but has underperformed broad market indices consistently.

These factors collectively contribute to the current valuation and price levels observed in Epigral's shares.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →